BNGO · Bionano Genomics, Inc.
$1.18
+0.00 (+0.00%)
At close · Aug 14
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, based on recurring losses from operations incurred since inception, the expectation of continued operating losses, and the need to raise additional capital to finance our future operations, we determined that there is substantial doubt about our ability to continue as a going concern within 12 months after the date that the financial statements included in this Quarterly Report are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$13.90M
Shares
11.78M
Bionano Genomics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Bionano Genomics, Inc. (BNGO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲73%
$6.67M
−$32.16M
'22 Q2
22-08-04
▲55.1%
$7.22M
−$31.81M
'22 Q3
22-11-03
▲30.4%
$8.21M
−$38.68M
'22 Q4
23-01-05
▲30.2%
$7.42M
−$37.12M
'23 Q1
23-04-24
▲29.9%
$8.66M
−$38.91M
'23 Q2
23-08-09
▲29%
$9.32M
−$112.57M
'23 Q3
23-10-11
▲30.5%
$10.72M
−$43.89M
'23 Q4
24-01-08
▲18.3%
$8.77M
−$31.42M
'24 Q1
24-05-08
▼10.3%
$7.77M
−$16.22M
'24 Q2
24-08-07
▼34.8%
$6.07M
−$44.25M
'24 Q3
24-11-13
▼26.4%
$6.46M
−$3.10M
'25 Q1
25-05-14
▼13.4%
$6.73M
−$6.86M
'25 Q2
25-08-14
▲21.3%
$7.37M
−$8.50M
'25 Q3
25-11-13
▼2.6%
$7.95M
−$7.93M
'25 Q4
26-03-23
▲3.6%
$6.69M
−$8.30M
'26 Q1
26-05-13
LATEST
▲21.4%
$8.17M
−$7.42M
'26 Q2
26-08-10
Earnings call
FY26 · Q2
2026-08-10
2026 BIONANO SECOND QUARTER FINANCIAL RESULTS CALL
Revenue
$8.17M
▲ 21.4% YoY Diluted EPS
$-0.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Bionano Genomics, Inc. Q1 FY2026 Earnings Call
Positive tone
OGM Installed Base & Utilization
Reimbursement & CPT Codes
Publications & Clinical Evidence
Revenue
$6.69M
▲ 3.6% YoY Diluted EPS
$-0.76
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-23
Bionano Genomics, Inc. Q4 FY2025 Earnings Call
Positive tone
OGM scaling and key customer adoption
Gross margin and cost transformation
Reimbursement and guideline inclusion
Revenue
$7.95M*
▼ 2.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Bionano Genomics, Inc. Q3 FY2025 Earnings Call
Positive tone
Routine user utilization strategy
Publications and clinical evidence
Revenue and product mix
Revenue
$7.37M
▲ 21.3% YoY Diluted EPS
$-1.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Bionano Genomics, Inc. Q2 FY2025 Earnings Call
Positive tone
VIA software and digital pathology expansion
Strategic shift to routine user focus
Flow cell consumables growth
Revenue
$6.73M
▼ 13.4% YoY Diluted EPS
$-1.99
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Bionano Genomics, Inc. Q1 FY2025 Earnings Call
Balanced tone
Strategic shift to routine/high-utilization users
Cost reduction and profitability
Publications and clinical evidence
Revenue
$6.46M
▼ 26.4% YoY Diluted EPS
$-1.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q3
2024-11-13
Bionano Genomics, Inc. Q3 FY2024 Earnings Call
Cautious tone
Consumables utilization and flow cell growth
Stratys system commercialization
Revenue decline and guidance reduction
Revenue
$6.07M
▼ 34.8% YoY Diluted EPS
$-30.92
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Bionano Genomics, Inc. Q2 FY2024 Earnings Call
Cautious tone
Stratys system adoption
Software and partnerships (VIA, Revvity)
Reimbursement and CPT code milestone
Revenue
$7.77M
▼ 10.3% YoY Diluted EPS
$-14.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Bionano Genomics, Inc. Q1 FY2024 Earnings Call
Positive tone
Biopharma and OGM adoption
Ionic purification system
Cost reduction and cash runway
Revenue
$8.77M
▲ 18.3% YoY Diluted EPS
$-35.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Bionano Genomics, Inc. Q4 FY2023 Earnings Call
Balanced tone
Revenue growth and installed base expansion
Stratys system adoption
Cost reduction and restructuring
Revenue
$10.72M*
▲ 30.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-11
Bionano Genomics, Inc. Q3 FY2023 Earnings Call
Revenue
$9.32M
▲ 29% YoY Diluted EPS
$-193.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Bionano Genomics, Inc. Q2 FY2023 Earnings Call
Revenue
$8.66M
▲ 29.9% YoY Diluted EPS
$-74.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-24
Bionano Genomics, Inc. Q1 FY2023 Earnings Call
Revenue
$7.42M
▲ 30.2% YoY Diluted EPS
$-73.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-05
Bionano Genomics, Inc. Q4 FY2022 Earnings Call
Revenue
$8.21M*
▲ 30.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Bionano Genomics, Inc. Q3 FY2022 Earnings Call
Revenue
$7.22M
▲ 55.1% YoY Diluted EPS
$-66.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Bionano Genomics, Inc. Q2 FY2022 Earnings Call
Revenue
$6.67M
▲ 73% YoY Diluted EPS
$-67.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Bionano Genomics, Inc. Q1 FY2022 Earnings Call
Revenue
$5.70M
▲ 79.8% YoY Diluted EPS
$-66.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Bionano Genomics, Inc. Q4 FY2021 Earnings Call
Revenue
$6.30M*
▲ 58% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Bionano Genomics, Inc. Q3 FY2021 Earnings Call
Revenue
$4.66M
▲ 112% YoY Diluted EPS
$-42.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Bionano Genomics, Inc. Q2 FY2021 Earnings Call
Revenue
$3.86M
▲ 226.2% YoY Diluted EPS
$-42.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Bionano Genomics, Inc. Q1 FY2021 Earnings Call
Revenue
$3.17M
▲ 178.9% YoY Diluted EPS
$-24.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-07
Bionano Genomics, Inc. Q4 FY2020 Earnings Call
Revenue
$3.99M*
▲ 43% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Bionano Genomics, Inc. Q3 FY2020 Earnings Call
Revenue
$2.20M
▼ 33.7% YoY Diluted EPS
$-48.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-24
Bionano Genomics, Inc. Q2 FY2020 Earnings Call
Revenue
$1.18M
▼ 45.7% YoY Diluted EPS
$-54.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-14
Bionano Genomics, Inc. Q1 FY2020 Earnings Call
Revenue
$1.14M
▼ 38.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Bionano Genomics, Inc. Q4 FY2019 Earnings Call
Revenue
$2.79M
▼ 30.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–26 of 26 earnings calls
Key facts
CIK
1411690
CUSIP
09075F404
13F (30d)
36 filings
36 filers
Visit website
Investor relations